Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab with Carboplatin and Cabazitaxel in Aggressive Variant Prostate Cancer
NCT05563558Phase 2Recruiting
- Sponsor
- OncoSur
- Start
- May 2023
- Primary completion
- Nov 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in prostate cancer (PCa), sponsored by OncoSur. Started May 2023; status: recruiting.
02
Drugs
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05563558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05563558.